Live financial news intelligence

Track market-moving stories before they get noisy

Real-time pulse of financial headlines curated from 5 premium feeds.

Latest market signal Czech Filtered by asset BBIO

Coverage 92,333 Raw stories ingested 7,957 rewritten in CS_CZ • 0 to rewrite (last 2 days).

Symbols 2,727 Assets with fetched stories

Cryptocurrencies BTC 4,261 ETH 3,079 SOL 1,751 XRP 1,689 USDC 969 HYPE 828

Stocks SPCX 879 MU 724 NVDA 684 MSFT 558 GOOGL 531 TSLA 504

Commodities GOLD 159 SILVER 93 OIL 51 PLATINUM 5 PALLADIUM 2 COPPER 1

Forex EURUSD 147 GBPUSD 143 USDCAD 51 USDJPY 37 AUDUSD 33 NZDUSD 23

1,679 with rewritten stories in CS_CZ • Hot assets ranked by fetched stories.

Agents 7 waiting Pipeline agents

FMP Stock News Fetch every minute 25s ago
FMP Forex News Fetch every 5 min 1m ago
CoinGecko News Fetch every 5 min 1m ago
FIO Stock News Fetch every 10 min 25s ago
Patria Stock News Fetch every 10 min 25s ago
Editorial rewrite Rewrite every minute 25s ago
Asset sync Assets every 1 hour 10m ago

Latest coverage

Market News Feed

Scan headlines quickly, then expand any story for source context.

Category Source Ticker

Relevance

Clear

Details	Date	Content	Source	Relevance
	Saved 2026-07-22 12:44 3d ago Published 2026-07-22 07:30 3d ago	FDA přijala NDA společnosti BridgeBio k posouzení pro encaleret BridgeBio oznámila, že FDA přijala k posouzení její NDA pro encaleret u ADH1. Agentura stanovila cílové datum rozhodnutí na 8. května 2027. BBIO BridgeBio Pharma	FMP Stock News	92
Original source text July 22, 2026 07:30 ET \| Source: BridgeBio Pharma, Inc. - PDUFA target action date of May 8, 2027 - If approved, encaleret will be the first and only approved therapy specifically indicated for individuals living with ADH1, representing a potential blockbuster opportunity for BridgeBio - Encaleret demonstrated consistent efficacy across all pre-specified primary and key secondary efficacy endpoints normalizing key markers of CaSR-driven disease biology without the need for calcium and vitamin D supplements, with a favorable safety and tolerability profile - BridgeBio is also currently enrolling CALIBRATE-PEDS, a registrational Phase 2/3 trial to study encaleret in pediatric ADH1 and intends to initiate the RECLAIM-HP Phase 3 registrational study of encaleret in chronic hypoparathyroidism later this summer; successful development could extend encaleret’s utility to a broader patient population PALO ALTO, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, today announced the FDA has accepted for filing its New Drug Application (NDA) for encaleret for the treatment of individuals living with autosomal dominant hypocalcemia type 1 (ADH1). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of May 8, 2027, and BridgeBio is prepared to launch encaleret upon approval, representing a potential blockbuster opportunity for the Company. The FDA also notified the Company that it is not currently planning to hold an advisory committee meeting to discuss the application. "The FDA's acceptance of our NDA is a powerful validation of encaleret’s differentiated clinical profile and enables a major step forward for the ADH1 community. We believe encaleret has the potential to transform care for patients who currently have no indicated treatment options, and we're moving with urgency to bring it to them,” said Ananth Sridhar, Chief Executive Officer of BridgeBio Endocrinology. CALIBRATE, the Phase 3 clinical trial of encaleret in ADH1, successfully achieved all pre-specified primary and key secondary efficacy endpoints, supporting encaleret’s potential as a disease-modifying therapy by targeting the underlying genetic cause of ADH1. The topline results can be found here. Additional results were presented at the European Congress of Endocrinology (ECE) 2026 and the Endocrine Society 2026 annual meeting (ENDO) in oral presentations, with data showing simultaneous restoration of blood and urine calcium, as well as restoration of physiologic parathyroid hormone (PTH) production. "For too long, ADH1 has been an invisible condition, that disrupts several systems in the body, from the kidneys to the nervous system to the muscles and often goes unrecognized for years. The path to diagnosis is frequently a long and exhausting one, especially for patients with a genetic disorder. Patients often cycle through specialists before anyone connects the dots to their diagnosis. The FDA's acceptance of this NDA is a moment of real hope for ADH1 patients and a signal that the medical and regulatory community understand the seriousness of this condition and that an orally administered option may finally be on the horizon for those in need," said Patty Keating, Executive Director of the HypoPARAthyroidism Association. As of April 2026, over 2,100 individuals have been diagnosed in the U.S. with autosomal dominant hypocalcemia since October 2023 based on claims data, suggestive of a growing marketplace and elevated diagnostic suspicion. The Company also intends to submit a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the use of encaleret in ADH1 in the second half of 2026. BridgeBio is currently enrolling CALIBRATE-PEDS (NCT07080385), a global registrational Phase 2/3 study of encaleret in pediatric ADH1. The Company also plans to initiate RECLAIM-HP, a global Phase 3 study of encaleret in chronic hypoparathyroidism later this summer, building on the positive Phase 2 proof-of-concept findings of PTH-independent effects of encaleret on renal calcium handling and expanding the potential applications of encaleret beyond ADH1. Successful development could extend encaleret’s utility to a broader patient population. About Autosomal Dominant Hypocalcemia Type 1 (ADH1) ADH1 is a common form of genetic hypoparathyroidism caused by gain-of-function variants in the calcium-sensing receptor gene (CASR). The calcium-sensing receptor (CaSR) constantly monitors and balances blood calcium levels by regulating parathyroid hormone secretion and calcium reabsorption in the kidneys. Individuals with ADH1 typically experience hypocalcemia, hypercalciuria, and inappropriately low levels of PTH. Symptoms of hypocalcemia may include severe muscle cramps, muscle spasms (tetany), a burning or prickling sensation in the hands or feet (paresthesia), brain fog, fatigue, and seizures. Hypercalciuria may result in kidney calcification (nephrocalcinosis), kidney stones (nephrolithiasis), and kidney failure. About Encaleret Encaleret is an investigational, orally administered small molecule under investigation to treat ADH1 and chronic hypoparathyroidism, that is designed to selectively negatively modulate the calcium sensing receptor. Encaleret has been granted Fast Track Designation by the U.S. FDA and Orphan Drug Designation in the U.S., European Union, and Japan. About BridgeBio BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok. BridgeBio Forward-Looking Statements This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), which are usually identified by the use of words such as “anticipates,” “believes,” “continues,” “estimates,” “expects,” “hopes,” “intends,” “may,” “plans,” “projects,” “remains,” “seeks,” “should,” “will,” and variations of such words or similar expressions. BridgeBio intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements include express and implied statements relating to the Company’s expectations regarding the regulatory review process for encaleret in ADH1, including the FDA’s review of the NDA and the potential for approval; the Company’s preparedness to launch encaleret upon approval; the potential for encaleret to become the first and only approved therapy specifically indicated for individuals living with ADH1 and to transform care for patients with ADH1; the potential for encaleret to be a disease-modifying therapy by targeting the underlying genetic cause of ADH1; the potential commercial opportunity for encaleret in ADH1, including as a potential blockbuster opportunity for the Company; the timing of a potential Marketing Authorization Application submission to the European Medicines Agency for encaleret in ADH1; the Company’s plans to initiate RECLAIM-HP, a global Phase 3 study of encaleret in chronic hypoparathyroidism, and the potential expansion of encaleret beyond ADH1, including the potential for encaleret to become a multi-billion-dollar opportunity for the Company. Such statements reflect the Company’s current views about the Company’s plans, intentions, expectations and strategies, which are based on the information currently available to it and on assumptions the Company has made. Although the Company believes that its plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, the Company can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, initial and ongoing data from the Company’s clinical trials not being indicative of final data, the design and success of ongoing and planned clinical trials, future regulatory filings, approvals and/or sales, despite having ongoing and future interactions with the FDA or other regulatory agencies to discuss potential paths to registration for the Company’s product candidates, the FDA or such other regulatory agencies not agreeing with the Company’s regulatory approval strategies, components of the Company’s filings, such as clinical trial designs, conduct and methodologies, or the sufficiency of data submitted, regulatory submissions not being accepted or approved on anticipated timelines or at all, encaleret not becoming the first and only approved therapy specifically indicated for individuals living with ADH1, the Company not being successful in launching encaleret on anticipated timing or at all, the potential commercial opportunity for encaleret not being realized, the Company’s plans for RECLAIM-HP not proceeding as expected, the impacts of current macroeconomic and geopolitical events, including changing conditions from hostilities in Ukraine and in Israel and the Middle East, increasing rates of inflation and changing interest rates, on business operations and expectations, as well as those risks set forth in the Risk Factors section of the Company’s most recent Annual Report on Form 10-K and the Company’s other filings with the U.S. Securities and Exchange Commission. Moreover, the Company operates in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of the Company’s management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, BridgeBio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. BridgeBio Media Contact: Bubba Murarka, Executive Vice President [email protected] (650)-789-8220 BridgeBio Investor Contact: Chinmay Shukla, Senior Vice President, Strategic Finance [email protected]
	Saved 2026-07-13 17:25 12d ago Published 2026-07-13 12:25 12d ago	Ionis po neúspěchu studie prudce klesá AstraZeneca a Ionis Pharmaceuticals oznámily, že studie CARDIO-TTRansform u Wainua nesplnila primární cíl. Akcie Ionis v jeden den spadly o více než 9 %; AstraZeneca jen krátce klesla během intradenního obchodování. BBIO BridgeBio Pharma	FMP Stock News	78
Original source text When a late-stage clinical trial misses a primary endpoint, the market reaction rarely distributes evenly across the board. The fallout often reveals undeniable fundamental truths about single-asset exposure, pipeline diversification, and the competitive moats protecting established treatments. The July 9 announcement from AstraZeneca NYSE: AZN and Ionis Pharmaceuticals NASDAQ: IONS regarding the CARDIO-TTRansform Phase 3 trial provides a real-time masterclass in these market dynamics. The investigational use of Wainua, also known as eplontersen, failed to achieve statistical significance on its primary composite endpoint of cardiovascular mortality and recurrent cardiovascular events at 140 weeks. The treatment targets transthyretin-mediated amyloid cardiomyopathy. This fatal disease causes misfolded proteins to build up in the heart muscle. Get Astrazeneca alerts: The clinical failure removes an anticipated competitor from a highly lucrative market and triggers an immediate capital rotation across the broader biotech sector. Unmasking the Trial: Stabilizers Block the PathTo truly understand why the market repriced these assets so aggressively, investors must look beneath the headline failure and evaluate the underlying subgroup data. The treatment landscape relies heavily on stabilizer medications like Vyndamax, manufactured by Pfizer NYSE: PFE. In the CARDIO-TTRansform trial, patients already taking these baseline stabilizers accounted for 57% of the study population at the start of the program, and that proportion rose to roughly 80% by the conclusion of the study. Wainua failed to demonstrate an additive treatment effect in this specific stabilizer subgroup. The drug did not improve outcomes for patients who were already receiving standard-of-care treatments. In the monotherapy subgroup, which includes patients not taking any stabilizers, Wainua demonstrated a hazard ratio of 0.71, translating to a 29% risk reduction. While that figure aligns closely with competitor benchmarks, it offers very little commercial utility. A pharmaceutical product cannot successfully capture meaningful market share if it only works for the rapidly shrinking fraction of patients who are completely naive to standard-of-care treatments. This data exposes a fundamental disparity between antisense oligonucleotides like Wainua and RNA interference therapies developed by competitors. Alnylam Pharmaceuticals NASDAQ: ALNY previously validated its competing RNA interference therapy, Amvuttra, across both monotherapy and combination with a stabilizer subgroup in its HELIOS-B trial. By failing to show that essential additive benefit, Wainua is effectively locked out of the most lucrative and pre-treated segment of the total addressable market. Asymmetric Damage: Single Asset SqueezeThe financial damage stemming from this clinical miss was distributed quite unevenly, highlighting the stark contrast between concentrated pipeline risk and structural business diversification. Ionis Pharmaceuticals Today IONS Ionis Pharmaceuticals $56.31 -1.94 (-3.33%) As of 01:25 PM Eastern This is a fair market value price provided by Massive. Learn more. 52-Week Range$40.03▼ $86.74Price Target$96.05 Ionis Pharmaceuticals absorbed the brunt of the impact. Shares fell by more than 9% in a single day, pushing the stock down more than 26% since the start of the year and compressing its total market capitalization to $9.63 billion. Ionis Pharmaceuticals faces acute vulnerability due to its reliance on expanding the addressable market for Wainua. The current regulatory approval for ATTR-polyneuropathy covers fewer than 50,000 patients globally. The cardiomyopathy indication would have unlocked a total addressable market of 300,000 to 500,000 patients. Without that expansion, Ionis Pharmaceuticals faces a difficult fundamental reality. The developer currently generates negative earnings, with an earnings-per-share loss of 56 cents. First-quarter 2026 revenue surged to $246 million, an 87% increase year-over-year, but rapid commercial infrastructure expansion kept profit margins compressed, resulting in a net loss of $93 million. While the company's trailing return on equity remained deeply negative at -58.65%, its balance sheet risk softened substantially after Ionis eliminated $633 million in convertible debt using restricted escrow cash on April 1, 2026. Astrazeneca Today $168.76 -2.85 (-1.66%) As of 01:25 PM Eastern This is a fair market value price provided by Massive. Learn more. 52-Week Range$137.23▼ $212.71Dividend Yield2.57% P/E Ratio25.35 Price Target$211.00 AstraZeneca tells a completely different fundamental story. AstraZeneca's stock price fell briefly intraday before institutional buyers stepped in to support it. A $266.54 billion pharmaceutical sector giant does not live or die by a single indication expansion. AstraZeneca generates $60.44 billion in annual sales, supported by blockbuster oncology franchises such as Tagrisso and Imfinzi. The company operates with a healthy 17.19% net margin, a robust 30.86% return on equity, and a conservative debt-to-equity ratio of 0.52. Pre-trial models projected Wainua could reach peak sales of up to $6.5 billion with the ATTR-CM approval. Analysts have since revised those estimates down to approximately $4 billion. Erasing a $2.5 billion premium certainly adjusts near-term valuation models, but it barely registers against AstraZeneca's stated $80 billion top-line revenue target for 2030. The institutional market accurately perceived the drop as a temporary mispricing rather than a structural downgrade. The Vultures Circle: Rivals Catch the TailwindsMarkets dislike a vacuum. When Wainua was removed as an imminent competitive threat, capital immediately rotated into the rival drugmakers positioned to capture that unaddressed market share. The trial failure preserves the current duopoly and triopoly pricing power within the disease space. BridgeBio NASDAQ: BBIO emerged as the most direct beneficiary, with shares up 16% to touch new 52-week highs following the initial announcement. BridgeBio is actively launching its newly approved therapy, Attruby. Without Wainua entering the market to compress margins and force aggressive discounting, BridgeBio enjoys a heavily cleared commercial runway. BridgeBio recently secured a $1 billion Series A convertible preferred equity raise led by Sixth Street and KKR. This infusion provides a substantial capital buffer to execute an aggressive, unopposed commercial launch, funding sales force deployment without immediate dilution concerns. Pfizer and Alnylam Pharmaceuticals also experienced immediate bid support. Pfizer maintains its multi-billion-dollar stronghold with Vyndamax, resting easy knowing that physicians will not have to weigh the transition of stable patients to a competing therapy. Alnylam Pharmaceuticals sustains its clinical momentum, as its RNA interference mechanism remains the only proven combination therapy that effectively stacks on top of existing stabilizers. Discharging the Risk: Portfolio Lessons LearnedThe failure of the CARDIO-TTRansform trial fundamentally rewrites the competitive map for amyloidosis treatments. It draws a hard line between therapies that can improve the standard of care and those that merely match it in isolation. For the entities involved, the data reinforces the protective power of a diversified revenue base. AstraZeneca easily absorbs the setback through its oncology and metabolic divisions, while Ionis Pharmaceuticals faces prolonged fundamental pressure as it navigates elevated debt levels and stalled growth drivers. Investors evaluating biotech allocations might consider prioritizing developers with validated combination therapies or deeply diversified pipelines to mitigate these specific clinical risks. Should You Invest $1,000 in Astrazeneca Right Now?Before you consider Astrazeneca, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astrazeneca wasn't on the list. While Astrazeneca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates. Get This Free Report
	Saved 2026-07-10 19:51 15d ago Published 2026-07-10 13:25 15d ago	BBIO vyskočila na 52týdenní maximum 93,42 USD po selhání AstraZenecy BridgeBio Pharma vyskočila na 52týdenní maximum 93,42 USD poté, co rival AstraZeneca selhala ve fázi III studie CARDIO-TTRansform. Akcie BBIO v seanci přidaly 15 %. BBIO BridgeBio Pharma	FMP Stock News	78
Original source text Key Takeaways BridgeBio Pharma surged after a rival's phase III ATTR-CM trial failed its primary endpoint.BBIO's Attruby is its only marketed drug and posted strong U.S. sales after its FDA approval.BridgeBio sees a large ATTR-CM opportunity as diagnoses rise and the market remains underdiagnosed. Shares of BridgeBio Pharma (BBIO - Free Report) climbed to a 52-week high of $93.42 on Thursday after rival AstraZeneca's (AZN - Free Report) late-stage clinical setback boosted investor confidence in the company's sole marketed drug, Attruby. Although the stock did not hold on to its intraday high, it still ended the session 15% higher, adding roughly $2.3 billion to its market value. The rally followed AstraZeneca’s announcement that the phase III CARDIO-TTRansform study evaluating Wainua in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) failed to meet its primary endpoint. Investors viewed the setback as a favorable development for BridgeBio's Attruby because it could strengthen the drug’s competitive position in the ATTR-CM space. Attruby is currently BridgeBio's only marketed product and the primary driver of the company's revenues. Approved by the FDA in November 2024 for adults with ATTR-CM, the drug has enjoyed a strong commercial launch. BridgeBio generated $362.4 million in U.S. Attruby sales in 2025, its first full year on the market, followed by nearly $181 million in the first quarter of 2026 alone. Attruby's long-term opportunity remains substantial because the target market continues to be significantly underdiagnosed. BridgeBio estimates that the number of diagnosed ATTR-CM patients in the United States grew from fewer than 5,000 in 2019 to more than 50,000 in 2025, while the global market opportunity for ATTR therapies could ultimately exceed $20 billion. Another company that benefited from AstraZeneca’s clinical setback is Pfizer (PFE - Free Report) , whose shares also rose 1% yesterday. The U.S.-based pharma giant currently dominates the ATTR-CM market with its Vyndaqel family, comprising Vyndaqel, Vyndamax and Vynmac. The franchise generated approximately $1.6 billion in global sales in first-quarter 2026, up 8% year over year, underscoring its leadership in the space. In April, Pfizer entered into a settlement with generic drug manufacturers that extends the effective U.S. patent protection for Vyndamax until June 1, 2031, delaying generic competition and supporting the drug's long-term commercial outlook. BBIO’s Price Performance, Valuation & EstimatesShares of BridgeBio have risen 18% year to date, outperforming the industry’s 3% growth. Image Source: Zacks Investment Research From a valuation standpoint, the company is currently trading at a premium to the industry. Based on the price-to-sales (P/S) ratio, the stock trades at 13.46 times forward 12-month sales, higher than the industry average of 1.95 times. Image Source: Zacks Investment Research Estimates for BridgeBio’s 2026 and 2027 bottom line have declined over the past 30 days. Image Source: Zacks Investment Research BBIO currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
	Saved 2026-07-08 17:29 17d ago Published 2026-07-08 13:25 17d ago	BridgeBio závisí na Attruby a chystá tři uvedení na trh BridgeBio závisí hlavně na Attruby, která v roce 2025 přinesla tržby 362,4 milionu USD a v 1. čtvrtletí roku 2026 téměř 181 milionů USD. Firma zároveň chystá tři možná uvedení na americký trh v příštích 12 měsících. BBIO BridgeBio Pharma	FMP Stock News	78
Original source text Key Takeaways BridgeBio's Attruby became its main revenue driver after strong early sales following FDA approval.BBIO targets three potential U.S. launches over 12 months, led by BBP-418 under priority review.BBIO boosted liquidity with $1B financing, but debt, competition and pipeline risks remain. BridgeBio Pharma (BBIO - Free Report) is moving from a launch-driven story toward a broader commercial execution test. Attruby has quickly become the company’s financial backbone, while late-stage pipeline assets could add new revenue streams. The stock’s outlook now depends on whether BridgeBio can scale Attruby, convert upcoming regulatory catalysts into launches and manage risks tied to a leveraged rare disease growth model. Why Attruby Drives BBIO GrowthAttruby is BridgeBio’s key marketed product and main revenue driver. The drug was approved by the FDA in November 2024 for adults with transthyretin amyloid cardiomyopathy (ATTR-CM), a progressive heart disease caused by transthyretin amyloid buildup. U.S. Attruby sales were $362.4 million in 2025, its first full year on the market, and nearly $181 million in the first quarter of 2026. That performance made the therapy BBIO’s financial backbone. Growth is tied to rising diagnosis rates, physician adoption and patient uptake. BridgeBio estimates that diagnosed U.S. ATTR-CM patients rose from fewer than 5,000 in 2019 to more than 50,000 in 2025, helped by greater awareness and wider use of non-invasive diagnostic tools. How BridgeBio Can Broaden RevenueBridgeBio’s next challenge is reducing its dependence on Attruby. The company is preparing for three potential U.S. product launches over the next 12 months, led by BBP-418, encaleret and infigratinib. BBP-418 is the closest catalyst. The FDA accepted the filing for priority review in limb-girdle muscular dystrophy type 2I/R9, with a decision expected by Nov. 27, 2026. Approval would make it the first therapy for this patient population. Encaleret adds another possible first-in-class launch. BridgeBio submitted the filing in May 2026 for autosomal dominant hypocalcemia type 1 (ADH1) and anticipates a U.S. launch in early 2027 if approved. Infigratinib could follow in achondroplasia. BridgeBio intends to file in the third quarter of 2026 and is targeting a potential launch in early to mid-2027. Together, these programs could shift BBIO toward a broader rare disease platform. BBIO Balance Sheet Supports Launch PlansBridgeBio recently raised $1 billion through preferred equity financing to support current and potential product launches. The capital gives the company more flexibility as it funds Attruby commercialization. Liquidity looks adequate for near-term needs. BridgeBio ended the first quarter of 2026 with $940.2 million in cash, cash equivalents and marketable securities, up from $587.5 million at the end of 2025. Debt remains part of the investment case. Long-term debt was approximately $1.93 billion as of March 31, 2026, while short-term debt was around $547 million. The cash balance covers near-term obligations, but BBIO remains a leveraged growth story. Where BBIO Investors Should Stay CautiousThe biggest risk is concentration. Attruby is BridgeBio’s only approved product in its commercial portfolio, leaving near-term financial performance highly dependent on one therapy. Competition is another constraint. Pfizer (PFE - Free Report) markets the established Vyndaqel family in ATTR-CM, and BridgeBio must keep proving Attruby’s clinical and access position to gain further share. Pipeline risk is also material. An FDA delay, rejection, request for more data or narrower-than-expected label for BBP-418, encaleret or infigratinib could push out the diversification timeline. In achondroplasia, BioMarin Pharmaceutical (BMRN - Free Report) markets Voxzogo, an injectable treatment option. That backdrop means infigratinib’s oral profile may help, but uptake would still depend on data, reimbursement and physician adoption. How BBIO Fits a Neutral Rating SetupBBIO fits a balanced setup because the positives and risks are both clear. Attruby has delivered meaningful early revenue, the late-stage pipeline offers multiple catalysts and the balance sheet has been strengthened. At the same time, one-product reliance, regulatory uncertainty and competition keep the risk-reward profile from being one-sided. The stock trades at 12.3X forward 12-month EV/Sales, above the Zacks sub-industry multiple of 2.7X. A Neutral stance is consistent with a Zacks Rank #3 (Hold) style setup, where investors may prefer to watch execution rather than assume a straight-line growth path. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
	Saved 2026-07-01 13:01 24d ago Published 2026-07-01 07:30 24d ago	BridgeBio získala až 1 miliardu USD na růst a uvedení na trh BridgeBio získala až 1 mld. USD v preferenčním kapitálu od Sixth Street a HealthCare Royalty, což výrazně posiluje bilanci firmy. Financování má podpořit růst Attruby i tři potenciální uvedení na trh v USA během příštích 12 měsíců. BBIO BridgeBio Pharma	FMP Stock News	92
Original source text - Preferred equity investment led by Sixth Street and with participation from HealthCare Royalty, a business of KKR, with an initial conversion price of approximately $138 per share (more than 100% premium to Company’s 30-day VWAP) - The financing significantly strengthens the Company’s balance sheet, enabling it to efficiently allocate capital across its highest return opportunities - The financing comes at a pivotal moment for the Company, as Attruby® continues to grow into a multi-billion-dollar blockbuster drug, and as BridgeBio prepares for three additional potential blockbuster U.S. product launches over the next 12 months across BBP-418 for LGMD2I/R9, encaleret for ADH1, and infigratinib for achondroplasia PALO ALTO, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, today announced that it has entered into an agreement with funds managed by Sixth Street (“Sixth Street”) and funds managed by HealthCare Royalty, a business of KKR (“HCRx” and, together with Sixth Street, the “Purchasers”) under which the Purchasers have invested up to $1 billion in newly issued convertible preferred equity of the Company. The Series A Cumulative Convertible Participating Preferred Stock has the following principal terms: 7.00% initial dividend, payable in kind or in cash at the Company’s electionInitial conversion price of $137.79 per share (more than 100% premium to BridgeBio’s 30-day volume-weighted average price), increasing to $153.10 per share (more than 125% premium) from the fifth anniversaryPermanent equity with no scheduled maturity and no redemption at the holder’s optionBridgeBio may redeem the preferred stock for cash or, in certain circumstances, convert it into common stock, in each case on the terms set forth in the definitive agreements Sixth Street funded $800M as the lead investor, and HealthCare Royalty funded $133.9M at today’s close of the preferred equity investment. “We are privileged to be partnering with Sixth Street and HealthCare Royalty at this pivotal time in BridgeBio’s trajectory. This financing represents the best of our dual mission – 1) to put patients first and ensure that we have the resources to do so, and 2) that we execute those responsibilities in a manner that maximizes the economic value of our Firm. Access to this type and quantum of capital ensures we can deliver on the promise of our launching medicines and beyond,” said Neil Kumar, Ph.D., Co-Founder and CEO of BridgeBio. “Sixth Street is proud to support BridgeBio’s mission of bringing meaningful medicines to patients during this exciting stage as the company is on the cusp of potential approval and launch of three important new therapies,” said Jeff Pootoolal, Partner at Sixth Street. “Providing flexible capital at scale to leading developers of transformative medicines is central to what we do, and we look forward to a long and productive partnership with the BridgeBio team." “The BridgeBio management team has a proven track record in launching and developing life-changing therapies, and we are pleased to partner with them on this transaction,” said Clarke Futch, Chairman and CEO of HealthCare Royalty. “This capital support reaffirms our belief in the company’s growth and ability to bring to market multiple products that serve high unmet medical needs.” Latham & Watkins LLP served as legal advisor to BridgeBio. Evercore served as financial advisor and Sullivan & Cromwell LLP and Mintz LLP served as legal advisors to Sixth Street. Gibson, Dunn & Crutcher LLP served as legal advisor to HealthCare Royalty. Additional details about the transaction and the related definitive agreements will be included in a Current Report on Form 8-K to be filed by the Company. About BridgeBio Pharma, Inc. BridgeBio Pharma, Inc. (BridgeBio; Nasdaq: BBIO) exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, and YouTube. About Sixth Street Sixth Street is a global investment firm with over $130 billion in assets under management and committed capital. Sixth Street uses its long-term flexible capital, data-enabled capabilities, and One Team culture to develop themes and offer solutions to companies across all stages of growth. Sixth Street Healthcare and Life Sciences invests thematically throughout the healthcare ecosystem, providing flexible capital solutions to companies addressing our most pressing healthcare challenges and improving patient outcomes. Investments in the sector include Apellis Pharmaceuticals, Arrowhead Pharmaceuticals, Arsenal Biosciences, Beam Therapeutics, Biohaven, Blueprint Medicines, Caris Life Sciences, Chroma Medicine, ConcertAI, Datavant, Essential Pharma, Immunogen, Ironwood, Mammoth Biosciences, Paratek Pharmaceuticals, and Velocity Clinical Research, among many others. Founded in 2009, Sixth Street has more than 750 team members including approximately 300 investment professionals around the world. For more information, visit https://www.sixthstreet.com/, or follow Sixth Street on LinkedIn. About HealthCare Royalty HealthCare Royalty (“HCRx”) is a leading royalty acquisition company founded in 2006 that is majority owned by KKR & Co. Inc. (NYSE: KKR). Over two decades, the HCRx team has developed a strong track record of investing in commercial-stage and near-commercial-stage biopharmaceutical assets, committing $7+ billion in over 110 biopharmaceutical products. With offices in New York, Stamford, San Francisco, Boston, London and Miami, HCRx continues to advance biopharmaceutical innovation by providing innovative capital solutions to counterparties. For more information, visit https://www.hcrx.com. HEALTHCARE ROYALTY®, HEALTHCARE ROYALTY PARTNERS® and HCRx® are registered trademarks of HealthCare Royalty Management, LLC BridgeBio Pharma, Inc. Forward-Looking Statements This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), which are usually identified by the use of words such as “anticipates,” “believes,” “continues,” “estimates,” “expects,” “hopes,” “intends,” “may,” “plans,” “projects,” “remains,” “seeks,” “should,” “will,” and variations of such words or similar expressions. BridgeBio intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements include express and implied statements relating to the Company’s expectations regarding its anticipated growth and expected product launches and intentions for investing in indication expansions. Such statements reflect the Company’s current views about the Company’s plans, intentions, expectations and strategies, which are based on the information currently available to it and on assumptions the Company has made. Although the Company believes that its plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, the Company can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, initial and ongoing data from the Company’s clinical trials not being indicative of final data, the design and success of ongoing and planned clinical trials, future regulatory filings, approvals and/or sales, despite having ongoing and future interactions with the FDA or other regulatory agencies to discuss potential paths to registration for the Company’s product candidates, the FDA or such other regulatory agencies not agreeing with the Company’s regulatory approval strategies, components of the Company’s filings, such as clinical trial designs, conduct and methodologies, or the sufficiency of data submitted, the impacts of current macroeconomic and geopolitical events, including changing conditions from hostilities in Ukraine and in Israel and the Gaza Strip, increasing rates of inflation and changing interest rates, on business operations and expectations, as well as those risks set forth in the Risk Factors section of the Company’s most recent Annual Report on Form 10-K and the Company’s other filings with the U.S. Securities and Exchange Commission. Moreover, the Company operates in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of the Company’s management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, BridgeBio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.